Senores Pharmaceuticals balance sheet

As of Sep 2026

Total assets: ₹1,681cr+30.5% on Sep 2025
Shareholders' equity: ₹1,032cr+23.6% on Sep 2025
Total debt: ₹394cr+70.2% on Sep 2025
Cash and investments: ₹18.0cr−79.1% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025

Non-current assets
	360	331	199
	31.1	17.5	44.2
	24.8	24.6	0.0
	46.6	46.6	38.2
	109	107	54.3
	311	232	128
	5.9	4.3	0.0
	0.0	4.2	0.0
	18.9	10.2	5.2
	24.8	18.7	5.2
	2.3	0.0	18.7
	4.7	—	7.4
	914	791	504
Current assets
	97.6	89.3	56.6
	253	325	124
	18.0	45.6	105
	82.7	114	280
	224	173	117
	578	657	626
	90.5	66.0	39.5
	766	812	722
	1,681	1,604	1,227
Equity
	46.1	46.1	46.1
	957	888	740
	1,003	934	786
	28.6	30.9	26.1
	1,032	965	812
Liabilities
	213	195	162
	19.2	13.2	8.2
	232	208	171
	5.4	6.6	3.3
	0.0	0.6	0.0
	237	215	174
	182	132	142
	151	235	67.2
	15.8	19.4	9.6
	348	386	219
	7.2	2.7	2.1
	33.9	20.2	13.5
	22.0	14.8	6.0
	412	424	241
	649	639	415
	1,681	1,604	1,227
Assets — additional as-filed lines
	0.0	13.9	9.4
Trade payables — MSME split
	3.1	11.9	15.5
	148	223	51.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SENORES₹1,324.30

Senores Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSANOFI INNOVACAP MOREPENLAB IOLCP FDC PGHL SANOFICONR ORCHPHARMAMcap ₹6,098 Cr

View

In ₹ Crore except Per Share As of	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	198.9	331.4	359.9
+ Capital Work-in-Progress	44.2	17.5	31.1
+ Investment Property	0.0	24.6	24.8
+ Goodwill	38.2	46.6	46.6
+ Other Intangibles	54.3	106.8	109.1
+ Intangibles under Development	128.3	232.0	311.1
+ Non-current Investments	0.0	4.3	5.9
+ Long-term Loans	0.0	4.2	0.0
+ Other Non-current Financial Assets	5.2	10.2	18.9
Non-current Financial Assets	5.2	18.7	24.8
+ Deferred Tax Assets	18.7	0.0	2.3
+ Other Non-current Assets	7.4	—	4.7
Total Non-current Assets	504.4	791.4	914.3
Current Assets
+ Inventories	56.6	89.3	97.6
+ Trade Receivables	123.9	324.8	253.2
+ Cash & Cash Equivalents	105.4	45.6	18.0
+ Other Bank Balances	280.1	114.1	82.7
+ Other Current Financial Assets	117.0	172.7	224.3
Current Financial Assets	626.4	657.1	578.2
+ Other Current Assets	39.5	66.0	90.5
Total Current Assets	722.4	812.4	766.3
Total Assets	1,226.9	1,603.8	1,680.6
Equity
+ Equity Share Capital	46.1	46.1	46.1
+ Other Equity / Reserves	740.1	887.6	956.9
Equity — Owners of Parent	786.2	933.6	1,003.0
+ Minority Interest	26.1	30.9	28.6
Total Equity	812.2	964.5	1,031.5
Liabilities
+ Borrowings — Non-current	162.5	194.9	212.9
+ Other Non-current Financial Liab	8.2	13.2	19.2
Non-current Financial Liabilities	170.7	208.1	232.1
+ Provisions — Non-current	3.3	6.6	5.4
+ Deferred Tax Liabilities	0.0	0.6	0.0
Non-current Liabilities	173.9	215.3	237.5
+ Borrowings — Current	142.3	132.2	181.6
+ Trade Payables	67.2	234.7	151.1
+ Other Current Financial Liab	9.6	19.4	15.8
Current Financial Liabilities	219.1	386.3	348.5
+ Provisions — Current	2.1	2.7	7.2
+ Current Tax Liabilities	13.5	20.2	33.9
+ Other Current Liabilities	6.0	14.8	22.0
Current Liabilities	240.7	424.0	411.6
Total Liabilities	414.6	639.3	649.1
Total Equity & Liabilities	1,226.9	1,603.8	1,680.6
Assets — additional as-filed lines
+ Biological Assets (other than bearer plants)	9.4	13.9	0.0
Trade Payables — MSME split
+ Dues to Micro & Small — Current	15.5	11.9	3.1
+ Dues to Other Creditors — Current	51.7	222.8	147.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.